The DNA- encoded library screening-guided isolation and pharmacological characterization of the first small molecule AT1R allosteric ligands are reported, uncovering new mechanisms for precisely controlling the dynamic behavior of the AT1R with implications for drug development targeting this pathophysiologically important receptor family.
Abstract
Blockade of signaling through the angiotensin II type 1 receptor (AT1R), a prototypical G protein-coupled receptor (GPCR), by angiotensin receptor blockers (ARBs) is a major therapeutic approach to treating a wide variety of cardiovascular and renal diseases1. Like most GPCRs, the AT1R signals through two transducers, G proteins and β-arrestins2,3. Previous reports have described β-arrestin-biased peptide orthosteric agonists for the AT1R with potential therapeutic advantages over currently available unbiased ARBs4–6. Here we report the DNA- encoded library screening-guided isolation and pharmacological characterization of the first small molecule AT1R allosteric ligands. We use cryo-electron microscopy, double electron- electron resonance spectroscopy, molecular dynamics simulations, and targeted mutagenesis to determine their binding sites, binding modes and conformational mechanisms driving their unique and divergent modulatory effects on G protein and β-arrestin pathways. Our findings uncover new mechanisms for precisely controlling the dynamic behavior of the AT1R with implications for drug development targeting this pathophysiologically important receptor family.
Findings reveal a conserved intracellular allosteric activation mechanism across multiple class B GPCRs and identify SIM1 and its analogs as valuable chemical tools for investigating receptor-specific intracellular allosteric regulation and G protein-preferential signaling.
Qian He, Shan Hong, Wen Hu et al.· Acta Pharmacologica Sinica· 0 citations
Cryo-electron microscopy structures of GPR84 in both active and inactive states revealed how different ligands interact with GPR84, influencing its signaling pathways, and provided a structural basis for designing selective modulators of GPR84, which could lead to new therapeutic strategies for diseases involving immun...
Myung Kyung Choi, D. Park, Pankyung Kim et al.· Experimental and Molecular M...· 0 citations
Allosteric modulation is a fundamental aspect of G protein-coupled receptor (GPCR) regulation where molecules that bind to alternative sites outside the orthosteric pocket alter agonist-induced signalling responses. The advantages of allosteric modulators over traditional orthosteric agonists have positioned them a...
Thomas H. Harman, Timothy Noel, Ali Nokhbehzaim et al.· Nature Communications· 0 citations
Family A G-protein-coupled receptors (GPCRs) are typically described as monomers, yet growing evidence suggests that they can form dimers with distinct signalling properties1, 2–3. However, the mechanisms and therapeutic potential of such dimerization remain poorly understood. Here we show that AP-7-168, an optimized d...
Jie-Min Shen, T. Peddada, Konstantin E. Komolov et al.· Nature· 2 citations
This study established a native mass spectrometry platform to probe ligand-induced conformational heterogeneity at the GPCR intracellular interface and demonstrated the utility of nanobody-based nMS for evaluating the structural heterogeneity and dynamic landscapes of GPCRs.
A single molecule pulldown (SiMPull) assay is developed that reports on both relative GPCR:β-arr interaction strength and stoichiometry to uncover molecular diversity in β-arr coupling to the neuromodulatory metabotropic glutamate receptors (mGluRs), prototypical, dimeric family C GPCRs.
Dagan C. Marx, Alberto J. Gonzalez-Hernandez, Joon Lee et al.· Nature Communications· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.